Invasive Fungal Infection Market to grow with a CAGR of 3.80%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Invasive Fungal Infection Market.
According
to TechSci Research report, “Global Invasive Fungal Infection Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Invasive Fungal
Infection Market has valued at USD 6.99 billion in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 3.80%
through 2028. This can be due to
collaborations and partnerships among leading companies with a diverse approach
to merge the expertise of individual companies and to strengthen their position
in the market.
Increased
awareness plays a crucial role in driving the demand for treatments and
diagnostics in the Global Invasive Fungal Infection Market. Greater awareness
among healthcare professionals and the public about the signs, symptoms, and
risk factors of invasive fungal infections leads to earlier detection and
diagnosis. This results in more patients seeking medical attention when they
experience symptoms, allowing for timely treatment and better outcomes. Awareness
campaigns and education efforts can encourage healthcare providers to
incorporate fungal infection screening into their routine practice, especially
for high-risk patient populations. This proactive approach to screening helps
identify infections before they become severe. Heightened awareness often
drives investment in research and development of advanced diagnostic methods
for invasive fungal infections. As a result, more accurate and rapid diagnostic
tools become available, aiding in early detection and targeted treatment. In
some cases, fungal infections may be stigmatized or overlooked, leading to
delayed diagnosis and treatment. Increased awareness helps reduce the stigma
associated with these infections, encouraging individuals to seek medical help
without hesitation. Educated patients are more likely to engage in their
healthcare and advocate for their own well-being. Increased awareness empowers
patients to recognize the importance of timely diagnosis and treatment, leading
to better adherence to prescribed therapies.
Invasive
fungal infections (IFIs) are severe and potentially lethal infections resulting
from fungi infiltrating deep tissues, organs, or the bloodstream within the
human body. These infections can manifest in individuals with compromised
immune systems, such as those receiving chemotherapy or organ transplants, or
individuals with specific medical conditions like diabetes or HIV/AIDS.
In March 2023, GSK plc and SCYNEXIS, Inc. have
recently formed an exclusive licensing agreement for Brexafemme (ibrexafungerp
tablets), an FDA-approved antifungal medication designed to address
vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). Under this exclusive
arrangement, GSK gains the rights to market Brexafemme for VVC and RVVC
treatment while also continuing the development of ibrexafungerp. Ibrexafungerp
is currently in phase III clinical trials for the potential treatment of
invasive candidiasis (IC), a severe and life-threatening fungal infection. In
GSK's pipeline, infectious diseases and HIV research constitute a significant
portion, comprising about two-thirds. Brexafemme aligns well with GSK's
portfolio of first or best-in-class treatments, which includes late-stage
antibiotics such as gepotidacin, a potential groundbreaking antibiotic for
uncomplicated urinary tract infections (uUTI) - the first of its kind in over
two decades, and tebipenem, a promising candidate for the treatment of complicated
urinary tract infections (cUTI).
Limited
treatment options are a significant challenge in the Global Invasive Fungal
Infection Market. This challenge arises due to several factors, including the
limited number of antifungal drug classes available, the emergence of
antifungal resistance, and the complexity of managing fungal infections in
certain patient populations. The number of antifungal drug classes available
for the treatment of invasive fungal infections is relatively small compared to
antibiotics or other classes of drugs. The main classes of antifungal agents
include azoles, echinocandins, polyenes, and flucytosine. This limited arsenal
of drugs makes it challenging to treat infections, especially when resistance
to one or more drug classes emerges. The emergence of antifungal resistance,
particularly among fungal species like Candida and Aspergillus, poses a serious
threat to effective treatment. Resistance can develop due to factors such as
overuse or inappropriate use of antifungal drugs, making it even more
challenging to manage invasive fungal infections. Different fungal species have
varying susceptibility to antifungal drugs. Choosing the right antifungal agent
based on the specific fungal pathogen causing the infection is critical. In
some cases, susceptibility testing is necessary to guide treatment decisions.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
"Invasive Fungal Infection Market.”
Global Invasive Fungal Infection Market is
segmented based on Disease Type, Drug Type, and by region.
Based on Disease Type,
Global Invasive Fungal Infection Market is segmented into Candidaemi Caa and
Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis,
Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others. Cryptococcal
meningitis is a severe fungal infection that affects the membranes covering the
brain and spinal cord, known as the meninges. It is caused by the fungus
Cryptococcus neoformans. This type of meningitis is considered an opportunistic
infection, meaning it typically occurs in individuals with weakened immune
systems, such as those with HIV/AIDS, organ transplant recipients, or
individuals undergoing immunosuppressive therapy. Individuals with compromised
immune systems are at the highest risk of developing cryptococcal meningitis.
This includes people with advanced HIV/AIDS, those on immunosuppressive
medications (such as after organ transplantation or for autoimmune diseases),
and individuals with certain cancers. Cryptococcus neoformans typically enter
the body through inhalation of fungal spores present in the environment. Once
in the lungs, the fungus can disseminate through the bloodstream to the central
nervous system (CNS), leading to meningitis. The symptoms of cryptococcal
meningitis can be like those of other types of meningitis and may include
fever, headache, stiff neck, nausea, vomiting, and altered mental status.
Neurological symptoms may also occur, such as confusion, seizures, and vision
changes.
Based on Region, North America held the largest share in the Global Invasive Fungal Infection Market.
North America has one of the highest healthcare spending rates in the world.
This allows for the adoption of advanced medical technologies and therapies,
including the latest antifungal treatments, to manage invasive fungal
infections effectively. Many clinical trials for antifungal drugs are conducted
in North America, which not only advances medical knowledge but also provides
patients with access to cutting-edge treatments. Healthcare providers and the
public in North America generally have a high level of awareness regarding
fungal infections, which promotes early diagnosis and appropriate treatment.
Some
of the major companies operating in the Global
Invasive Fungal Infection Market include:
- Cidara
Therapeutics, Inc.
- Basilea
Pharmaceutica AG Allschwil
- Pfizer
Inc.
- GlaxoSmith
Kline
- Bayer
AG
- Abbott
Laboratories Ltd.
- Merck
& Co, Inc.
- Astellas
Pharma Inc.
- Scynexis
Inc.
- Matinas
BioPharma Holdings, Inc
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for the treatment of Invasive
Fungal Infections. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Invasive Fungal Infection Market in the forecast period,"
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Invasive Fungal Infection Market by Disease Type (Candidaemi Caa and Invasive
Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal
Candidiasis, Histoplasmosis Acute Pulmonary, Others), by Drug Type (Polyenes, Amphotericin
B Deoxycholate, Lipid Formulation Amphotericin B, Others), By
Region, By Competition Forecast
& Opportunities, 2018-2028F has
evaluated the future growth potential of Global Invasive Fungal Infection Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Invasive Fungal Infection Market.
Contact
Mr.
Ken Mathews
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States-
10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com